Updated:
Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biotech developing myeloid engagers and ADCs for solid tumors. Founded 2015, led by Randall Schatzman.
Bolt Biotherapeutics
Bolt Biotherapeutics was founded in 2015 to develop novel cancer immunotherapies. The company was built on a technology platform that combines antibodies with immune-stimulating components to engage myeloid cells against tumors (public record). Its core approach targets solid tumors, a space where many conventional immunotherapies have struggled. The firm's strategy centers on three therapeutic modalities: myeloid engagers, antibody-drug conjugates (ADCs), and bispecific antibodies. As of 2025, its lead candidate, BDC-1001, had reached Phase 1/2 clinical trials in HER2-positive solid tumors (per the firm's public announcements). Bolt Biotherapeutics operates primarily in the United States, with key research and development activities in California. Bolt Biotherapeutics disclosed a workforce reduction in early 2024, cutting approximately 35% of its staff to extend its cash runway through mid-2026 (per SEC filings, 2024). As of the latest public filings, the company's remaining team focused on advancing BDC-1001 and early-stage pipeline candidates. No additional offices or adjacent vehicles are publicly known. Structural insight: Bolt Biotherapeutics differentiates itself as a platform-driven biotech — its technology is designed to convert non-responsive tumors into responsive ones by stimulating myeloid cells, a mechanism distinct from T-cell directed approaches used by many competitors. This platform orientation, rather than a single-asset focus, shapes its research and development strategy and potential partnering opportunities.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Principals
Randall Schatzman
Chief Executive Officer
Edith Perez
Chief Medical Officer
Sector focus
Frequently asked questions
Who makes investment and operational decisions at Bolt Biotherapeutics?
Randall Schatzman serves as CEO and is responsible for overall strategy and operations. Edith Perez, as Chief Medical Officer, oversees clinical development. The board of directors provides governance oversight (public record).
What is the core technology platform of Bolt Biotherapeutics?
The company's platform uses immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with Toll-like receptor (TLR) agonists to activate myeloid cells in the tumor microenvironment. This differs from T-cell focused immunotherapies (per the firm's public disclosures).
What clinical stage has Bolt Biotherapeutics reached?
As of 2025, Bolt's lead candidate BDC-1001 was in Phase 1/2 trials for HER2-positive solid tumors. The company has prioritized this program following a strategic restructuring in early 2024 (per SEC filings, 2024).
Which therapeutic areas does Bolt Biotherapeutics focus on?
The firm exclusively targets oncology, with a focus on solid tumors — particularly those that have shown resistance to checkpoint inhibitors and other standard therapies. Its pipeline includes programs for HER2-positive gastric, breast, and colorectal cancers (public record).
Has Bolt Biotherapeutics reported partnership or collaboration activity?
Bolt Biotherapeutics has publicly disclosed a collaboration with the National Cancer Institute (NCI) to evaluate BDC-1001 in combination therapies. The firm has also engaged in early-stage research partnerships with academic institutions (per company releases).
What is the company's financial position as of the most recent public filing?
Following the February 2024 restructuring, Bolt Biotherapeutics reported that its cash runway extends through mid-2026. The company had approximately $85 million in cash and cash equivalents as of its Q1 2024 earnings report (per SEC filings).
How does Bolt Biotherapeutics' approach differ from other immuno-oncology companies?
Bolt focuses on stimulating the innate immune system through myeloid cell activation, rather than the adaptive T-cell pathway targeted by most checkpoint inhibitors and CAR-T therapies. This platform is designed to convert 'cold' tumors into 'hot' tumors, potentially expanding the number of patients who could benefit from immunotherapy (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: